Open House Drug Rebate Agreement Interferon beta-1a (Rebif), ATC L03AB07

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Jun 03, 2028 · 644 days left·Open·Supplies·Framework

Inscrivez-vous pour sauvegarder Open documents

Structured notice only

Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Interferon beta-1a, Fertigarzneimittelbezeichnung Rebif(R), ATC L03AB07

60/100

Score d'opportunité

PromisingLow complexity

SuppliesFrameworkOpen

Pourquoi ce score ?

Opportunité

60 / 100

Complexité

20 / 100

Facteurs de risque

No guaranteed volume; actual discount may be high with no return.

Contract can be superseded by future competitive contracts, leading to automatic termination.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

Description
Industries & Services
Capabilities
Market & Experience
Certifications

Aperçu

Strong opportunity

Faits clés

Framework procurement
Supplies contract
1 lot
Duration until Jul 2028
Non-exclusive rebate agreement for Interferon beta-1a (Rebif), ATC L03AB07.
Contract duration: August 2026 to July 2028.

Afficher le résumé complet

Open House (non-exclusive) rebate agreement for Interferon beta-1a (Rebif) offered by AOK Bayern. Any eligible pharmaceutical company can join by submitting required documents by monthly deadlines. The contract runs from August 2026 to July 2028. No estimated value provided.

Risques

No guaranteed volume; actual discount may be high with no return.

Contract can be superseded by future competitive contracts, leading to automatic termination.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

Must be a pharmaceutical company.

Certifications

Documents in German or accompanied by certified German translation.

Administrative

Submit signed contract, signed annex specifying the medicinal products, and signed declaration of reliability.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

Not applicable (open house – all eligible accepted).

Acheteur

Nom

AOK Bayern - Die Gesundheitskasse

Localisation

München, DEU

[email protected]

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open House Drug Rebate Agreement Interferon beta-1a (Rebif), ATC L03AB07

Non-exclusive rebate agreement for Interferon beta-1a (Rebif). Eligible pharmaceutical companies can sign identical, non-negotiable terms. Contract may be terminated if a competitive discount contract is concluded. Submission deadlines: 3rd of each month for next month start; final deadline 3 June 2028.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Jul 2026 - Jul 2028

Catégorie

Pharmaceutical products

Critères d'attribution

Not applicable (open house – all eligible accepted).

Date limite

Deadline Jun 03, 2028

Détails de la procédure

Date de publication: 14 Jun 2026
Langues: German

Métadonnées de référence

Base juridique: 32014L0024

Identifiants de référence

ID de l'appel d'offres: 406578-2026

Documents (2)

Document de consultation 1 Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3